AI-extracted from the 10-Q filed 2026-07-30 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenues rose 7% to $71.7B on pharmacy claims composition and higher Cigna Healthcare premium rates, lifting shareholders' net income 8% to $1.66B.
Biggest Revenue Drivers
Evernorth Health Services$61.5B+6% YoY
Increase due to claims composition in Pharmacy Benefit Services and higher claims volume from customer growth in Specialty and Care Services
Cigna Healthcare$11.8B+9% YoY
Higher premiums (+$664 million), mostly within employer insured and stop loss, primarily reflecting premium rate increases
Biggest Revenue Drivers
Total revenue: $71.7B+7% YoY
Evernorth Health Services$61.5B+6% YoY
Increase due to claims composition in Pharmacy Benefit Services and higher claims volume from customer growth in Specialty and Care Services
Within Evernorth Health Services
Pharmacy Benefit Services$34.5B+8% YoY
Claims composition, partially offset by lower claims volume (-2%)
Specialty and Care Services$27.0B+4% YoY
Customer and client growth in specialty pharmacy and care services
Cigna Healthcare$11.8B+9% YoY
Higher premiums (+$664 million), mostly within employer insured and stop loss, primarily reflecting premium rate increases
Other Operations$131M-29% YoY
Primarily driven by the discontinuation of certain small non-strategic businesses
Largest Expense Items
Pharmacy and other service costs$56.7B+6% YoY
Primarily reflecting changes in claims composition within Pharmacy Benefit Services
Medical costs and other benefit expenses$8.4B+9% YoY
Primarily reflecting higher medical costs within Cigna Healthcare
Selling, general and administrative expenses$3.5B+1% YoY
Includes $69 million pre-tax strategic optimization costs and $77 million of litigation charges
Amortization of acquired intangible assets$389M-8% YoY
Margins: Cigna Healthcare pre-tax margin rose 70 bps to 10.9%, though its medical care ratio worsened 130 bps to 84.5% on prior-year risk adjustment benefits in 2025; Evernorth pre-tax margin slipped 20 bps to 2.7%.
Watch Items from the Filing
Pharmacy Benefit Services pre-tax adjusted income fell 27% to $609 million on client- and customer-focused initiatives (-11%) and lower claims volume; pharmacy claim volume declined 2% to 537 million.
The Company announced in April 2026 a planned exit from the Individual and Family Plans medical business as of January 1, 2027; segment premiums were $860 million in the quarter.
Strategic optimization program cost $70 million pre-tax in the quarter and $1,199 million program-to-date, running through 2028, with $269 million accrued liability outstanding.
Reinsurance concentration: $3,054 million of recoverables from six reinsurers rated BBB+ or higher, 77% held by two Lincoln entities; Berkshire limit has ~$3.0 billion remaining.
Litigation charges of $77 million pre-tax were recorded in the quarter within Cigna Healthcare; accounts receivable allowances rose to $7.4 billion from $6.8 billion.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Wiseman Eric CDirectorGrant or award · Apr 22, 2026
Ozuah PhilipDirectorGrant or award · Apr 22, 2026
Congress trading in CI
43 transactions in CI reported by 13 members of Congress under the STOCK Act, most recent trade Mar 23, 2026. Reported transactions, not recommendations.
About Cigna Group (CI): stock profile, AI score and financials
Cigna Group (CI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CI at 66.1/100 on a composite quality score built from its SEC filings, placing it at rank #429 of 2,925 stocks — the top 25% of the AI-ranked universe. CI scores in the top quartile across revenue scale (99.5). Areas of concern include free cash flow (37.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Cigna Group reports quarterly revenue of $71.7B, net income of $1.7B, an operating margin of 3.7%. Top institutional holders of CI by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. CI trades on the NYSE exchange and files with the SEC under CIK 1739940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cigna Group directly from SEC EDGAR.